Quick Facts (as of 8 Oct 2025)
- Ticker / Exchange:NTLA – Nasdaq
- Latest intraday price: around $26.14 with daily trading between $20.31–$26.39 Indmoney. The previous day’s close was $20.44 Macrotrends.
- Market capitalisation: roughly $2.2 billion Indmoney, making Intellia a small‑cap biotech.
- 52‑week range:$6.28–21.08 Directorstalkinterviews with an intraday high above the previous 52‑week high following recent data releases Indmoney.
- Return metrics: shares have surged ~72.6 % over the past month and ~83.8 % over three months Indmoney but remain down about 63.5 % over three years Indmoney.
- Fundamentals: trailing‑12‑month revenue is $52.9 million with a –$4.11 EPS and a cash reserve of ≈$707 million (Q1 2025) Finimize. Debt‑to‑equity is low at 0.14 Gurufocus and the company holds enough cash to fund operations into the first half of 2027 Nasdaq.
- Analyst sentiment: The consensus rating is “Moderate Buy” with average price targets around $27–34, implying 30–100 % upside Marketbeat Nai500.
Recent Performance and News
Phase 1 data fuels rally
Intellia’s October rally was triggered by longer‑term Phase 1 results for nexiguran ziclumeran (nex‑z), an in‑vivo CRISPR therapy for transthyretin (ATTR) amyloidosis. A GlobeNewswire release (Sept 25 2025) reported that a single dose produced a rapid, deep and durable reduction of serum TTR levels—mean reduction 92 % at 24 months and 90 % at 36 months Globenewswire. Patients also showed clinical improvements or stabilization of neuropathy and cardiac markers Globenewswire, and safety findings were mostly mild infusion‑related events Globenewswire. CEO John Leonard said the data “demonstrate rapid, deep and durable TTR reductions with meaningful clinical improvements” and reiterated plans to complete enrolment in the Phase 3 MAGNITUDE‑2 trial in the first half of 2026 Globenewswire Globenewswire.
The strong data sparked buying. MarketBeat noted that on 8 October 2025 the stock jumped 6.6 % to $21.80 (intraday high $21.08), while trading volume was 88 % below average Marketbeat. Analysts responded with upgrades; HC Wainwright raised its price target from $25 to $30 Marketbeat, and the consensus target reached $27.95 Marketbeat. Simply Wall St highlighted that ARK Investment’s purchase of 99,000 shares after the data underscored investor optimism Simplywall.
Financial results and restructuring
In Q2 2025, Intellia reported collaboration revenue of $14.2 million, more than double the prior year and above analyst expectations Nasdaq. The net loss per share narrowed to $0.98 (vs. $1.52 in Q2 2024) Nasdaq, aided by reduced research and SG&A expenses as management trimmed headcount and streamlined programs Nasdaq. The company ended the quarter with $630 million in cash, projecting a runway into H1 2027 Nasdaq. Management is prioritising late‑stage programs; it discontinued NTLA‑3001 and cut the workforce by 27 % to extend the cash runway Nasdaq. Both lead programs – NTLA‑2002 for hereditary angioedema (HAE) and NTLA‑2001 (nex‑z) for ATTR – are now in Phase 3 trials Nasdaq.
Pipeline outlook
- NTLA‑2002 / lonvoguran ziclumeran (lonvo‑z): This in‑vivo CRISPR therapy aims for a one‑time cure for hereditary angioedema. Phase 1/2 data showed a 98 % reduction in monthly attack rates and all ten patients remained attack‑free Nasdaq. The Phase 3 HAELO trial is recruiting ahead of schedule, and a Biologics License Application (BLA) filing is planned for H2 2026 Nasdaq.
- NTLA‑2001 / nex‑z: Co‑developed with Regeneron, this therapy targets polyneuropathy and cardiomyopathy forms of ATTR. The Phase 3 MAGNITUDE trials are enrolling; 650 patients are expected by year‑end 2025 with potential expansion to 1,200 Nasdaq. The program has Regenerative Medicine Advanced Therapy (RMAT) designation, allowing for accelerated review.
Fundamental and Technical Analysis
Financial strength and valuation
GuruFocus notes that Intellia’s revenue of ~$52.9 million has grown at 7.9 % annually, but the company runs at a –968 % operating margin and –908 % net margin Gurufocus. Intellia maintains a current ratio of 5.19, debt‑to‑equity of 0.14 and cash ratio of 4.81, reflecting a solid liquidity position Gurufocus. The Altman Z‑score (~2.1) and Piotroski F‑score (2) indicate elevated bankruptcy risk Gurufocus.
Valuation multiples are high: price‑to‑sales (P/S) about 49 x and price‑to‑book (P/B) around 3.76 Gurufocus. The stock’s beta of 2.77 signifies high volatility Gurufocus. Finimize estimates an EV/sales ratio of 9.9 x and a negative free‑cash‑flow yield of –50.5 %, implying the market values potential future revenue rather than current earnings Finimize.
Technical indicators
Recent momentum has driven the shares far above longer‑term averages. DirectorsTalk reports that the 50‑day moving average was $12.78 and 200‑day average $10.45, with the RSI (14) at 68.56 – near overbought territory Directorstalkinterviews. MarketBeat data show the stock’s beta of 2.37, reinforcing volatility Marketbeat. Despite the rally, Intellia’s stock trades well below prior highs; Macrotrends lists a 52‑week high of $21.49 and low of $5.90 Macrotrends, making the recent close near $26 intraday a new multiyear high.
Expert Commentary
- CEO John Leonard emphasized that the Phase 1 data show “rapid, deep and durable TTR reductions with meaningful clinical improvements” and that enrollment for Phase 3 is on track Globenewswire.
- Finimize highlights Intellia’s strong patent portfolio, RMAT designations and disciplined cost management, noting that the company cut 27 % of staff and consolidated offices to save $51 million, leaving $707.1 million in cash as of March 2025 Finimize.
- Finimize also points out that Intellia trades at a significant valuation premium (EV/sales ~9.87 x) and warns of negative free cash flow and binary clinical outcomes Finimize. Its analysts assign a “Moderate Buy” rating with an average target of $37.56, while cautioning that volatility (beta 2.17) and negative margins make NTLA a high‑risk, high‑reward investment Finimize.
- NAI500 notes that Intellia’s 63 % year‑to‑date rally could be just the beginning, citing a consensus price target of $34.64, with some bullish estimates suggesting a ten‑fold increase in valuation based on potential peak sales of $5 billion for NTLA‑2002 and $12 billion for NTLA‑2001 Nai500. Analysts caution, however, that the therapies may not reach market before 2027 and reimbursement hurdles could limit uptake Nai500.
- MarketBeat reports that most analysts rate the stock Buy, with 13 Buy, six Hold and two Sell ratings. HC Wainwright recently raised its target to $30, Guggenheim to $14, Chardan to $60, and Citizens JMP to $33 Marketbeat.
Competitive Landscape
CRISPR Therapeutics (CRSP)
- Stock price: ~$77.77 (8 Oct 2025) Indmoney. 52‑week range $30.04–$73.95 Indmoney.
- Market cap: ~$6.4 billion Indmoney.
- Pipeline: Ex‑vivo gene‑editing therapy CASGEVY (exa‑cel) for sickle cell disease and β‑thalassemia has been approved; Q2 2025 results showed 75 authorized treatment centers, 115 patients cell‑collected and 29 infusions Crisprtx. Pipeline also includes CTX310/320 (cholesterol modulation) and CTX112/131 (allogeneic CAR‑T), with up to 82 % reduction in triglycerides for CTX310 Crisprtx. The company held $1.7 billion in cash as of June 30 2025 Crisprtx.
Editas Medicine (EDIT)
- Stock price: ~$4.29 (8 Oct 2025) Indmoney. 52‑week range $0.91–4.07 Indmoney.
- Market cap: ~$341 million Indmoney.
- Developments: The company pivoted toward in‑vivo gene up‑regulation and expects to declare two development candidates (HSC and liver) by mid‑2025 Globenewswire. Editas terminated its reni‑cel program, reduced workforce and reported a net loss despite a cash runway into Q2 2027 Globenewswire.
Beam Therapeutics (BEAM)
- Stock price: ~$27.49 Indmoney. 52‑week range $13.53–35.25 Indmoney.
- Market cap: ~$2.6 billion Indmoney. Beam focuses on base‑editing and has multiple preclinical programs; no near‑term pivotal trial yet.
Outlook and Forecasts
Short‑term (12 months)
Positive momentum could continue if Intellia maintains investor excitement around Phase 3 progress. Analyst price targets cluster in the $27–35 range Marketbeat Nai500. Simply Wall St’s fair‑value estimates range widely, from $4.61 to $34.08, reflecting the binary nature of gene‑editing outcomes Simplywall. Key catalysts over the next year include:
- Interim data from the NTLA‑2002 Phase 3 HAELO trial – expected to show whether attack‑free rates seen in Phase 1/2 can be replicated in a larger cohort.
- MAGNITUDE Phase 3 enrollment progress and potential early efficacy signals – success could accelerate the timeline for a BLA submission.
- Regulatory developments – RMAT designation could lead to expedited reviews; however, any safety issues could spark severe drawdowns.
- Collaborative revenue and cost management – Intellia’s ability to secure milestone payments from Regeneron and manage expenses will influence cash runway and dilution risk.
Given the stock’s volatility (beta >2) and high short interest earlier in 2025 Finimize, traders should expect sharp swings around news. A breakout above $30 could invite momentum investors, while failure to meet trial timelines might send shares back toward the low teens.
Long‑term (3+ years)
By 2027‑28 Intellia aims to commercialise its first products. If NTLA‑2002 and NTLA‑2001 reach the market, revenue could jump into the multi‑billion‑dollar range. NAI500 cites potential peak sales of $5 billion for NTLA‑2002 and $12 billion for NTLA‑2001 Nai500. Achieving even a fraction of those sales would justify a much higher valuation; some analysts project revenue of $648.6 million and earnings of $104 million by 2028 Simplywall. However, the path is fraught with risks:
- Clinical uncertainty: Phase 3 gene‑editing trials carry significant risk. Any adverse events could delay or derail programs.
- Reimbursement and access: One‑time gene therapies may cost over $1 million per patient Nai500, and payers might balk at coverage without clear long‑term benefits.
- Competitive pressure: CRISPR Therapeutics already markets CASGEVY and is advancing cholesterol‑lowering therapies Crisprtx; Editas and Beam are developing next‑generation editing technologies. Success by competitors could erode Intellia’s market share.
Conclusion
Intellia Therapeutics sits at the forefront of in‑vivo CRISPR gene editing. Its share price has surged following compelling Phase 1 data and early Phase 3 momentum, yet valuation remains tied to future success of two lead programs. With a strong cash position and high analyst enthusiasm, NTLA offers outsized upside, but investors must be comfortable with clinical, regulatory and market‑access risks. In the near term, watch for further data releases and analyst upgrades; over the longer term, the stock’s fate will hinge on whether its gene‑editing therapies prove safe, effective and commercially viable.
In summary, Intellia Therapeutics (NTLA) is a small-cap biotech entering pivotal territory with its CRISPR-based therapies. Despite a 72% monthly surge and new multiyear highs, the company’s valuation hinges on the success of two Phase 3 programs, NTLA‑2002 and NTLA‑2001. Long-term data from these trials show durable reductions in disease markers and have prompted analyst upgrades, yet the road to commercialisation remains fraught with scientific, regulatory and reimbursement risks Globenewswire Finimize.
I note that Intellia’s financial health is solid; it holds over $630 million in cash, a low debt-to-equity ratio, and a cash runway through at least 2027 Nasdaq. However, the company is unprofitable, trades at a high price-to-sales multiple, and faces stiff competition from CRISPR Therapeutics, Editas and Beam Therapeutics Gurufocus. Short-term catalysts include Phase 3 readouts and regulatory milestones, while long-term prospects depend on whether its one-time gene therapies can achieve multi-billion-dollar peak sales and secure payer support Nai500. Investors considering NTLA should weigh its high potential rewards against significant volatility and binary clinical outcomes.
